Scienceblogtwo

In lung cancer screening volunteers, cytisine may be a secure and efficient smoking cessation treatment, according to a recent study published in the Journal of Thoracic Oncology. Cytisine, a plant-based alkaloid produced from Cytisus laburnum, has been authorized for use as a smoking cessation aid in Europe since the 1960s. It selectively stimulates nicotinic acetylcholine receptors in a small amount. The two smoking cessation medications that are now FDA-approved in the United States are varenicline and bupropion. In 2018, the Food and Drug Administration granted permission for a research in the US to assess cytisine's efficacy. Researchers from the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, under the direction of Dr. Ugo Pastorino, established the single-center, randomized controlled trial known as the Screening and Multiple Intervention on Lung Epidemics (SMILE) study to examine the efficacy and safety of cytisine as a smoking cessation therapy during low-d...

Pain is a vital alarm system that warns us of tissue damage and compels us to leave potentially dangerous situations, despite the fact that it is uncomfortable. Although it is assumed that pain will lessen as wounds heal, many individuals continue to experience it even after they have recovered. Currently, a new study with an unexpected connection to lung cancer suggests potential new treatments for persistent pain. An international group of researchers from IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Harvard Medical School, and Boston Children's Hospital led the project, which was reported in Science Translational Medicine. The research, which was carried out using laboratory mouse models, revealed several therapeutic possibilities that could help the globe better manage chronic pain and stop the opioid pandemic. An key risk signal is acute pain. Contrarily, chronic pain is a result of a lingering injury and can even occur in the absence of a s...